Fidelity Investments’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.86M | Buy |
1,335,328
+209,690
| +19% | +$288K | ﹤0.01% | 2662 |
|
|
2025
Q4 | $1.81M | Buy |
1,125,638
+213,817
| +23% | +$448K | ﹤0.01% | 2651 |
|
|
2025
Q3 | $2.49M | Buy |
911,821
+97,839
| +12% | +$325K | ﹤0.01% | 2469 |
|
|
2025
Q2 | $2.96M | Sell |
813,982
-58,502
| -7% | -$161K | ﹤0.01% | 2352 |
|
|
2025
Q1 | $1.68M | Buy |
872,484
+125,478
| +17% | +$256K | ﹤0.01% | 2506 |
|
|
2024
Q4 | $1.42M | Buy |
747,006
+64,968
| +10% | +$113K | ﹤0.01% | 2554 |
|
|
2024
Q3 | $900K | Buy |
682,038
+140,529
| +26% | +$188K | ﹤0.01% | 2632 |
|
|
2024
Q2 | $552K | Buy |
541,509
+38,265
| +8% | +$47.3K | ﹤0.01% | 2702 |
|
|
2024
Q1 | $921K | Sell |
503,244
-76,246
| -13% | -$122K | ﹤0.01% | 2528 |
|
|
2023
Q4 | $719K | Sell |
579,490
-58,600
| -9% | -$59.8K | ﹤0.01% | 2567 |
|
|
2023
Q3 | $727K | Buy |
638,090
+24,500
| +4% | +$31.5K | ﹤0.01% | 2533 |
|
|
2023
Q2 | $561K | Hold |
613,590
| – | – | ﹤0.01% | 2620 |
|
|
2023
Q1 | $344K | Hold |
613,590
| – | – | ﹤0.01% | 2817 |
|
|
2022
Q4 | $354K | Sell |
613,590
-3,528
| -0.6% | -$1.11K | ﹤0.01% | 2830 |
|
|
2022
Q3 | $195K | Sell |
617,118
-4,126
| -0.7% | -$1.62K | ﹤0.01% | 3058 |
|
|
2022
Q2 | $219K | Buy |
621,244
+397,243
| +177% | +$167K | ﹤0.01% | 3102 |
|
|
2022
Q1 | $161K | Buy |
+224,001
| New | +$479K | ﹤0.01% | 3305 |
|
|
2021
Q4 | – | Sell |
-37
| Closed | – | – | 4282 |
|
|
2021
Q3 | $0 | Buy |
+37
| New | +$106 | ﹤0.01% | 4279 |
|
|
2021
Q2 | – | Sell |
-280
| Closed | -$1K | – | 4185 |
|
|
2021
Q1 | $1K | Buy |
+280
| New | +$1.01K | ﹤0.01% | 3790 |
|
|
2020
Q4 | – | Sell |
-1,200
| Closed | -$3K | – | 3793 |
|
|
2020
Q3 | $3K | Sell |
1,200
-1,770,367
| -100% | -$15.5M | ﹤0.01% | 3381 |
|
|
2020
Q2 | $24.1M | Buy |
1,771,567
+745,500
| +73% | +$7.71M | ﹤0.01% | 1472 |
|
|
2020
Q1 | $7.78M | Buy |
1,026,067
+861,808
| +525% | +$6.7M | ﹤0.01% | 1776 |
|
|
2019
Q4 | $1.04M | Buy |
164,259
+57,091
| +53% | +$271K | ﹤0.01% | 2394 |
|
|
2019
Q3 | $420K | Sell |
107,168
-38,074
| -26% | -$163K | ﹤0.01% | 2541 |
|
|
2019
Q2 | $703K | Sell |
145,242
-66,426
| -31% | -$378K | ﹤0.01% | 2490 |
|
|
2019
Q1 | $1.73M | Sell |
211,668
-2,500
| -1% | -$17.2K | ﹤0.01% | 2329 |
|
|
2018
Q4 | $1.18M | Sell |
214,168
-460,710
| -68% | -$3.61M | ﹤0.01% | 2381 |
|
|
2018
Q3 | $5.96M | Sell |
674,878
-139,277
| -17% | -$1.25M | ﹤0.01% | 2097 |
|
|
2018
Q2 | $8.13M | Hold |
814,155
| – | – | ﹤0.01% | 2005 |
|
|
2018
Q1 | $7.76M | Hold |
814,155
| – | – | ﹤0.01% | 2026 |
|
|
2017
Q4 | $12.1M | Sell |
814,155
-222,800
| -21% | -$3.7M | ﹤0.01% | 1893 |
|
|
2017
Q3 | $20.4M | Hold |
1,036,955
| – | – | ﹤0.01% | 1691 |
|
|
2017
Q2 | $14.9M | Buy |
1,036,955
+105,100
| +11% | +$1.33M | ﹤0.01% | 1794 |
|
|
2017
Q1 | $8.57M | Hold |
931,855
| – | – | ﹤0.01% | 2026 |
|
|
2016
Q4 | $9.7M | Hold |
931,855
| – | – | ﹤0.01% | 1983 |
|
|
2016
Q3 | $8.43M | Sell |
931,855
-757,000
| -45% | -$6.43M | ﹤0.01% | 2046 |
|
|
2016
Q2 | $12.6M | Sell |
1,688,855
-300,400
| -15% | -$2.62M | ﹤0.01% | 1862 |
|
|
2016
Q1 | $17.9M | Buy |
1,989,255
+23,655
| +1% | +$192K | ﹤0.01% | 1718 |
|
|
2015
Q4 | $25.4M | Hold |
1,965,600
| – | – | ﹤0.01% | 1572 |
|
|
2015
Q3 | $19M | Hold |
1,965,600
| – | – | ﹤0.01% | 1678 |
|
|
2015
Q2 | $20.2M | Buy |
1,965,600
+1,241,400
| +171% | +$10.6M | ﹤0.01% | 1727 |
|
|
2015
Q1 | $8.05M | Hold |
724,200
| – | – | ﹤0.01% | 2077 |
|
|
2014
Q4 | $8.43M | Sell |
724,200
-275,200
| -28% | -$3.95M | ﹤0.01% | 2062 |
|
|
2014
Q3 | $22.1M | Sell |
999,400
-19,700
| -2% | -$453K | ﹤0.01% | 1692 |
|
|
2014
Q2 | $28.3M | Buy |
+1,019,100
| New | +$24.5M | ﹤0.01% | 1623 |
|
Other funds holding AKBA
VCM
VPM
Fidelity Investments's AKBA Position: Q1 2026 in Review
Fidelity Investments increased its Akebia Therapeutics (AKBA) stake by 19% in Q1 2026, buying an estimated $288K and bringing the position to 1,335,328 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2662.
Fidelity Investments first reported a position in AKBA in Q2 2014 and has held it in 45 quarters since. The position peaked at $28.3M in Q2 2014. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Fidelity Investments held 1,335,328 shares of Akebia Therapeutics worth $1.86M as of Q1 2026.
- Fidelity Investments bought 209,690 Akebia Therapeutics shares in Q1 2026, an estimated $288K.
- Akebia Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2662 holding.
- Fidelity Investments first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 45 quarters since.
- Fidelity Investments's Akebia Therapeutics position peaked at $28.3M in Q2 2014.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.